Citations 561

Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8092-8093

10.1182/blood-2022-164617

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10068-10070

10.1182/blood-2022-162754

High Prevalence of Epigenetic Mutations in Histiocytic and Dendritic Cell Disorders: Results from Molecular Analysis of a Large Cohort from Histiocytosis Working Group

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 32-33

10.1182/blood-2022-162855

Monocytopenia As an Adverse Prognosticator in Vexas Syndrome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 11406-11407

10.1182/blood-2022-165706

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10017-10019

10.1182/blood-2022-167181

Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9363-9365

10.1182/blood-2022-168232

Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3995-3996

10.1182/blood-2022-159714

Gastrointestinal Manifestation of Langerhans Cell Histiocytosis

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12259-12260

10.1182/blood-2022-165511

Sarcopenia identified by computed tomography imaging using a deep learning–based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma

Cancer | November 22, 2022 | Volume: 129 | Issue: 3 | Pages: 385-392

10.1002/cncr.34545 | PMID 36413412

BackgroundSarcopenia increases with age and is associated with poor survival outcomes in patients with cancer. By using a deep learning–based segmentation approach, clinical computed tomography (CT) images of the abdomen of patients with newly diagnosed multiple myeloma (NDMM) were reviewed to determine whether the presence of sarcopenia had any prognostic value.MethodsSarcopenia was detected by accurate segmentation and measurement of the skeletal muscle components present at the level of the L3 vertebrae. These skeletal muscle measurements were further normalized by the height of the patient to obtain the skeletal muscle index for each patient to classify them as sarcopenic or not.ResultsThe study cohort consisted of 322 patients of which 67 (28%) were categorized as having high risk (HR) fluorescence in situ hybridization (FISH) cytogenetics. A total of 171 (53%) patients were sarcopenic based on their peri‐diagnosis standard‐dose CT scan. The median overall survival (OS) and 2‐year mortality rate for sarcopenic patients was 44 months and 40% compared to 90 months and 18% for those not sarcopenic, respectively (p < .0001 for both comparisons). In a multivariable model, the adverse prognostic impact of sarcopenia was independent of International Staging System stage, age, and HR FISH cytogenetics.ConclusionsSarcopenia identified by a machine learning–based convolutional neural network algorithm significantly affects OS in patients with NDMM. Future studies using this machine learning–based methodology of assessing sarcopenia in larger prospective clinical trials are required to validate these findings.
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients

American Journal of Hematology | November 20, 2022 | Volume: 98 | Issue: 2 | Pages: No page available

10.1002/ajh.26786 | PMID 36403135